Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $21,256.67 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 34,847 shares of the stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $0.61, for a total value of $21,256.67. Following the completion of the sale, the director owned 2,515,827 shares of the company’s stock, valued at approximately $1,534,654.47. This trade represents a 1.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Luke Evnin also recently made the following trade(s):

• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total transaction of $15,476.44.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $40,921.83.
• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.05, for a total transaction of $15,275.40.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $25,294.80.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ:HOWL traded up $0.01 on Friday, reaching $0.64. 346,654 shares of the company’s stock were exchanged, compared to its average volume of 894,149. The business’s 50-day moving average is $1.00 and its two-hundred day moving average is $1.27. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.56 and a fifty-two week high of $2.38. The firm has a market capitalization of $31.30 million, a price-to-earnings ratio of -0.40 and a beta of 0.78.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the period. Jane Street Group LLC acquired a new position in shares of Werewolf Therapeutics in the second quarter worth $409,000. Citadel Advisors LLC purchased a new stake in shares of Werewolf Therapeutics during the 3rd quarter worth about $304,000. Finally, Marshall Wace LLP acquired a new stake in Werewolf Therapeutics in the second quarter valued at approximately $113,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on HOWL shares. Wedbush cut Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research report on Friday, December 19th. Citizens Jmp downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Bank of America dropped their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.